At the moment, two clinical trials are ongoing to test the safety and efficacy of Brentuximab vedotin (BV), a CD30-directed antibody–drug conjugate, which is already approved by the US FDA for the treatment of classic Hodgkin lymphoma (cHL). This evidence concerns the gene TNFRSF8 and classic Hodgkin lymphoma.